Holen Sie sich die Stockscreener-App
73.09
3.00%
2.13
Schlusskurs vom Vortag:
$70.96
Offen:
$71.13
24-Stunden-Volumen:
606.67K
Relative Volume:
0.84
Marktkapitalisierung:
$2.18B
Einnahmen:
$442.68M
Nettoeinkommen (Verlust:
$-77.81M
KGV:
-27.39
EPS:
-2.6684
Netto-Cashflow:
$-28.65M
1W Leistung:
-17.32%
1M Leistung:
-15.72%
6M Leistung:
+10.41%
1J Leistung:
-37.73%
1-Tages-Spanne:
$70.48
$74.86
1-Wochen-Bereich:
$70.48
$89.32
52-Wochen-Spanne:
$32.21
$170.87
Genedx Holdings Corp Stock (WGS) Company Profile
Firmenname
Genedx Holdings Corp
Sektor
Branche
Telefon
888-729-1206
Adresse
333 LUDLOW STREET, STAMFORD
Compare WGS vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
WGS
Genedx Holdings Corp
|
73.09 | 2.64B | 442.68M | -77.81M | -28.65M | -2.6684 |
TMO
Thermo Fisher Scientific Inc
|
654.80 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
214.06 | 157.81B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
410.35 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
167.78 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
258.21 | 44.50B | 16.63B | 1.39B | 2.12B | 8.0674 |
Genedx Holdings Corp Stock (WGS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-10-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-07-09 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-15 | Eingeleitet | Guggenheim | Buy |
| 2025-05-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-07-10 | Eingeleitet | Craig Hallum | Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
Alle ansehen
Genedx Holdings Corp Aktie (WGS) Neueste Nachrichten
GeneDx Holdings Corp (WGS) Stock Down 4.6% -- Now Undervalued? GF Score: 69/100 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages GeneDx Holdings Corp. (WGS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
GeneDx Holdings Corp (WGS) Shares Fall 11.8% -- GF Value Says St - GuruFocus
GeneDx to report Q2 2026 financial results on August 3 - scanx.trade
Discipline and Rules-Based Execution in WGS Response - Stock Traders Daily
GeneDx Holdings Corp. (WGS) options chain - Yahoo Finance Australia
A Look at GeneDx Holdings Corp (WGS) After 3.9% Gain -- GF Value $74.24 vs Price $88.48 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GeneDx Holdings Corp. (WGS) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
GeneDx Stock Is Down 30% In Last 1 Year, Can It Climb Again in 2027? - TIKR.com
A Look at GeneDx Holdings Corp (WGS) After 7.2% Decline -- GF Va - GuruFocus
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
GeneDx Holdings Corp (WGS) Stock Down 3.7% but Still Overvalued -- GF Score: 62/100 - GuruFocus
GeneDx CEO Katherine Stueland sells $1.03m in stock - Investing.com
GeneDx (WGS) CEO sells 10,501 shares to cover taxes - Stock Titan
Tax-driven stock sale by GeneDx (WGS) CFO after RSU vesting - Stock Titan
GeneDx Holdings (WGS) director receives 1,146 shares at no cash cost - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against GeneDx Holdings Corp. (WGS) And Encourages Investors to Reach Out - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - natlawreview.com
Is GeneDx Holdings Corp (WGS) Overvalued After 5.5% Rally? GF Va - GuruFocus
AWGS to BDT: GeneDx Holdings Corp aStock Price in Bangladeshi Taka - CoinGecko
How Genedx Holdings Corp. (WGS) Affects Rotational Strategy Timing - Stock Traders Daily
GeneDx (WGS) CEO sells shares in tax-withholding trade - Stock Titan
GeneDx (WGS) CFO sells stock for taxes, holds 41,476 shares - Stock Titan
WGS: GeneDx Holdings Corp Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C - Yahoo Finance
About two-thirds of U.S. patients with a rare genetic disease are undiagnosed. GeneDx offers free testing. - Stock Titan
GeneDx at Wells Fargo healthcare conference: growth and collections in focus - Investing.com Canada
GeneDx Holdings Corp. (WGS) Latest Stock News & Headlines - Yahoo! Finance Canada
GeneDx Holdings CFO Kevin Feeley Executes 717 Shares at $0 and Sells at $83.84 on Sept. 1, 2026 - Kalkine Media
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against GeneDx Holdings Corp. (WGS) And Encourages Shareholders to Reach Out - ACCESS Newswire
GeneDx Holdings (WGS) CFO sells shares in tax-cover trade - Stock Titan
Insider at GeneDx (NASDAQ: WGS) lines up new stock sale after June tax trades - Stock Titan
Planned $1.2M insider sale at GeneDx (NASDAQ: WGS) tied to 2026 RSU vesting - Stock Titan
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law Firm - Eastern Progress
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree - marketscreener.com
WGS Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against GeneDx Holdings Corp - Eastern Progress
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics AcquisitionHBSS - Eastern Progress
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit - Eastern Progress
WGS Shareholder Alert: GeneDx Holdings Corp. Securities Class Action LawsuitInvestors Should Contact The Gross Law Firm - Eastern Progress
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Investors to Connect - ACCESS Newswire
GeneDx Holdings (WGS) Study Data Puts Its Fair Value Debate Back In Focus - Sahm
A GeneDx study found genetic diagnoses in 63% of children with faltering growth - Stock Titan
A Look at GeneDx Holdings Corp (WGS) After 5.5% Gain -- GF Value $73.66 vs Price $87.06 - GuruFocus
GeneDx Holdings Corp. $WGS Shares Purchased by Bank of America Corp DE - MarketBeat
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates? - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages GeneDx Holdings Cor - The National Law Review
2026-08-18 | GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:WGS | Press Release - Stockhouse
GeneDx: Why I Think The Worst Is Behind The Business (NASDAQ:WGS) - Seeking Alpha
WGS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Inv - The National Law Review
WGS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce - The National Law Review
Finanzdaten der Genedx Holdings Corp-Aktie (WGS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Genedx Holdings Corp-Aktie (WGS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Sep 16 '26 |
Sale |
97.61 |
10,501 |
1,025,013 |
115,476 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 16 '26 |
Option Exercise |
0.00 |
7,197 |
0 |
48,673 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 16 '26 |
Sale |
97.61 |
3,728 |
363,892 |
44,945 |
| Fuchs Thomas | Director |
Sep 17 '26 |
Option Exercise |
0.00 |
1,146 |
0 |
1,146 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Sep 09 '26 |
Option Exercise |
0.00 |
6,547 |
0 |
110,919 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Sep 09 '26 |
Sale |
84.22 |
3,692 |
310,932 |
107,227 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 09 '26 |
Option Exercise |
0.00 |
2,462 |
0 |
42,761 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 09 '26 |
Sale |
84.22 |
1,285 |
108,220 |
41,476 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 01 '26 |
Option Exercise |
0.00 |
717 |
0 |
40,671 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 01 '26 |
Sale |
83.84 |
372 |
31,188 |
40,299 |
0.97%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):